Search reports, ask a question, or jump to a page.
The problem
Intervention: Nebulized tranexamic acid (TXA 100 mg/ml) administered in three 5-mL doses
Who it was tested with: Children presenting to emergency departments with secondary post-tonsillectomy hemorrhage.
Children or communities are compared with a group that did not receive the intervention, or followed over years. This is the design that best separates what the intervention did from everything else that changed.
"We designed the TranExamic Atomized for Pediatric post-Operative Tonsillectomy hemorrhage (TEAPOT) trial protocol to evaluate the feasibility of conducting a confirmatory clinical trial to evaluate the effects of TXA in children with PTH. We will randomize children presenting to the ED with secondary PTH to receive three 5-mL nebulized doses of either TXA (TXA 100 mg/ml) or placebo (normal saline)." This is a randomized controlled trial design, meeting the experimental evidence tier, but no efficacy outcome is yet known since this is a protocol document describing planned methodology rather than results.
This is a protocol document describing a planned pilot trial, not completed research. No outcomes data exist yet. The study is designed as a feasibility pilot rather than a definitive efficacy trial.
Across countries and designs
1 study · 1 country
